{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:45:59Z","timestamp":1788522359597,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s10557-023-07452-1","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T09:03:01Z","timestamp":1681376581000},"page":"937-945","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Recurrent Atherosclerotic Cardiovascular Disease Events Potentially Prevented with Guideline-Recommended Cholesterol-Lowering Therapy following Myocardial Infarction"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3865-9607","authenticated-orcid":false,"given":"Swati","family":"Sakhuja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera A.","family":"Bittner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Farkouh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily B.","family":"Levitan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika M.","family":"Safford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Woodward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoyan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nafeesa","family":"Dhalwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany","family":"Kalich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Exter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Muntner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Rosenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisandro D.","family":"Colantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,13]]},"reference":[{"issue":"3","key":"7452_CR1","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/clc.23160","volume":"42","author":"S Li","year":"2019","unstructured":"Li S, Peng Y, Wang X, et al. Cardiovascular events and death after myocardial infarction or ischemic stroke in an older Medicare population. Clin Cardiol. 2019;42(3):391\u20139.","journal-title":"Clin Cardiol"},{"issue":"19","key":"7452_CR2","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1093\/eurheartj\/ehu505","volume":"36","author":"T Jernberg","year":"2015","unstructured":"Jernberg T, Hasvold P, Henriksson M, et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015;36(19):1163\u201370.","journal-title":"Eur Heart J"},{"issue":"24","key":"7452_CR3","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","volume":"73","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al. 2018 Guideline on the Management of Blood Cholesterol. J Amer Coll Cardiol. 2019;73(24):e285\u2013350.","journal-title":"J Amer Coll Cardiol."},{"issue":"8","key":"7452_CR4","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.amjcard.2013.12.040","volume":"113","author":"MS Abdallah","year":"2014","unstructured":"Abdallah MS, Kosiborod M, Tang F, et al. Patterns and predictors of intensive statin therapy among patients with diabetes mellitus after acute myocardial infarction. Am J Cardiol. 2014;113(8):1267\u201372.","journal-title":"Am J Cardiol"},{"issue":"10","key":"7452_CR5","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.amjcard.2018.02.002","volume":"121","author":"DG Karalis","year":"2018","unstructured":"Karalis DG, Mallya UG, Ghannam AF, et al. Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia. Am J Cardiol. 2018;121(10):1155\u201361.","journal-title":"Am J Cardiol"},{"issue":"3","key":"7452_CR6","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s10557-021-07167-1","volume":"36","author":"P Muntner","year":"2022","unstructured":"Muntner P, Orroth KK, Mues KE, et al. Evaluating a Simple Approach to Identify Adults Meeting the 2018 AHA\/ACC Cholesterol Guideline Definition of Very High Risk for Atherosclerotic Cardiovascular Disease. Cardiovasc Drugs Ther. 2022;36(3):475\u201381.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"5","key":"7452_CR7","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.jacl.2021.08.001","volume":"15","author":"CL Colvin","year":"2021","unstructured":"Colvin CL, Poudel B, Bress AP, et al. Race\/ethnic and sex differences in the initiation of non-statin lipid-lowering medication following myocardial infarction. J Clin Lipidol. 2021;15(5):665\u201373.","journal-title":"J Clin Lipidol"},{"issue":"22","key":"7452_CR8","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1016\/j.jacc.2017.03.585","volume":"69","author":"RS Rosenson","year":"2017","unstructured":"Rosenson RS, Farkouh ME, Mefford M, et al. Trends in Use of High-Intensity Statin Therapy After Myocardial Infarction, 2011 to 2014. J Am Coll Cardiol. 2017;69(22):2696\u2013706.","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"7452_CR9","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.jacc.2018.02.032","volume":"71","author":"SAE Peters","year":"2018","unstructured":"Peters SAE, Colantonio LD, Zhao H, et al. Sex Differences in High-Intensity Statin Use Following Myocardial Infarction in the United States. J Am Coll Cardiol. 2018;71(16):1729\u201337.","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"7452_CR10","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1016\/j.jacc.2022.02.049","volume":"79","author":"LD Colantonio","year":"2022","unstructured":"Colantonio LD, Wang Z, Chen L, et al. Trends in High-Intensity Statin Therapy After Myocardial Infarction Among U.S. Adults, 2011\u20132019. J Amer Coll Cardiol. 2022;79(18):1870\u20132.","journal-title":"J Amer Coll Cardiol."},{"issue":"1","key":"7452_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"issue":"14","key":"7452_CR12","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","volume":"80","author":"DM Lloyd-Jones","year":"2022","unstructured":"Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for ldl-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the american college of cardiology solution set oversight committee. J Am Coll Cardiol. 2022;80(14):1366\u2013418.","journal-title":"J Am Coll Cardiol."},{"issue":"5","key":"7452_CR13","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1001\/jamacardio.2020.0013","volume":"5","author":"M Sampson","year":"2020","unstructured":"Sampson M, Ling C, Sun Q, et al. A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and\/or Hypertriglyceridemia. JAMA Cardiology. 2020;5(5):540\u20138.","journal-title":"JAMA Cardiology"},{"issue":"7","key":"7452_CR14","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1177\/2047487315598710","volume":"23","author":"BW Karlson","year":"2016","unstructured":"Karlson BW, Palmer MK, Nicholls SJ, Lundman P, Barter PJ. Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: Results from the VOYAGER meta-analysis. Eur J Prev Cardiol. 2016;23(7):744\u20137.","journal-title":"Eur J Prev Cardiol"},{"issue":"25","key":"7452_CR15","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387\u201397.","journal-title":"N Engl J Med"},{"issue":"18","key":"7452_CR16","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"22","key":"7452_CR17","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097\u2013107.","journal-title":"N Engl J Med"},{"issue":"9976","key":"7452_CR18","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","volume":"385","author":"J Fulcher","year":"2015","unstructured":"Fulcher J, O\u2019Connell R, Voysey M, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397\u2013405.","journal-title":"Lancet"},{"issue":"446","key":"7452_CR19","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. J Am Stat Assoc. 1999;94(446):496\u2013509.","journal-title":"J Am Stat Assoc"},{"issue":"2","key":"7452_CR20","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ahj.2015.04.027","volume":"170","author":"TM Brown","year":"2015","unstructured":"Brown TM, Deng L, Becker DJ, et al. Trends in mortality and recurrent coronary heart disease events after an acute myocardial infarction among Medicare beneficiaries, 2001\u20132009. Am Heart J. 2015;170(2):249\u201355.","journal-title":"Am Heart J"},{"issue":"9","key":"7452_CR21","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamacardio.2019.2481","volume":"4","author":"V Bittner","year":"2019","unstructured":"Bittner V, Colantonio LD, Dai Y, et al. Association of Region and Hospital and Patient Characteristics With Use of High-Intensity Statins After Myocardial Infarction Among Medicare Beneficiaries. JAMA Cardiology. 2019;4(9):865\u201372.","journal-title":"JAMA Cardiology"},{"issue":"8","key":"7452_CR22","doi-asserted-by":"publisher","first-page":"e019254","DOI":"10.1161\/JAHA.120.019254","volume":"10","author":"CG Derington","year":"2021","unstructured":"Derington CG, Colantonio LD, Herrick JS, et al. Factors Associated With PCSK9 Inhibitor Initiation Among US Veterans. J Amer Heart Assoc. 2021;10(8):e019254.","journal-title":"J Amer Heart Assoc."},{"issue":"14","key":"7452_CR23","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa050461","volume":"352","author":"JC LaRosa","year":"2005","unstructured":"LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425\u201335.","journal-title":"N Engl J Med"},{"issue":"3","key":"7452_CR24","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jacc.2014.09.088","volume":"65","author":"RS Rosenson","year":"2015","unstructured":"Rosenson RS, Kent ST, Brown TM, et al. Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease. J Am Coll Cardiol. 2015;65(3):270\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"7452_CR25","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1001\/jamacardio.2017.0911","volume":"2","author":"LD Colantonio","year":"2017","unstructured":"Colantonio LD, Huang L, Monda KL, et al. Adherence to High-Intensity Statins Following a Myocardial Infarction Hospitalization Among Medicare Beneficiaries. JAMA Cardiology. 2017;2(8):890\u20135.","journal-title":"JAMA Cardiology"},{"issue":"11","key":"7452_CR26","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.jacc.2016.12.036","volume":"69","author":"M-C Serban","year":"2017","unstructured":"Serban M-C, Colantonio LD, Manthripragada AD, et al. Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction. J Am Coll Cardiol. 2017;69(11):1386\u201395.","journal-title":"J Am Coll Cardiol"},{"issue":"34","key":"7452_CR27","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","volume":"43","author":"I Byty\u00e7i","year":"2022","unstructured":"Byty\u00e7i I, Penson PE, Mikhailidis DP, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022;43(34):3213\u201323.","journal-title":"Eur Heart J"},{"issue":"10355","key":"7452_CR28","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S0140-6736(22)01545-8","volume":"400","author":"C Reith","year":"2022","unstructured":"Reith C, Baigent C, Blackwell L, et al. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet. 2022;400(10355):832\u201345.","journal-title":"Lancet"},{"issue":"7","key":"7452_CR29","doi-asserted-by":"publisher","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","volume":"158","author":"H Zhang","year":"2013","unstructured":"Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158(7):526\u201334.","journal-title":"Ann Intern Med"},{"issue":"4","key":"7452_CR30","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jacl.2011.05.005","volume":"5","author":"LJ Harris","year":"2011","unstructured":"Harris LJ, Thapa R, Brown M, et al. Clinical and laboratory phenotype of patients experiencing statin intolerance attributable to myalgia. J Clin Lipidol. 2011;5(4):299\u2013307.","journal-title":"J Clin Lipidol"},{"issue":"3","key":"7452_CR31","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1345\/aph.1R509","volume":"47","author":"AJ Keating","year":"2013","unstructured":"Keating AJ, Campbell KB, Guyton JR. Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy. Ann Pharmacother. 2013;47(3):398\u2013404.","journal-title":"Ann Pharmacother"},{"issue":"10","key":"7452_CR32","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.jacc.2017.07.752","volume":"70","author":"RS Rosenson","year":"2017","unstructured":"Rosenson RS, Baker S, Banach M, et al. Optimizing Cholesterol Treatment in Patients With Muscle Complaints. J Am Coll Cardiol. 2017;70(10):1290\u2013301.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"7452_CR33","doi-asserted-by":"publisher","first-page":"e011246","DOI":"10.1161\/JAHA.118.011246","volume":"8","author":"AM Chamberlain","year":"2019","unstructured":"Chamberlain AM, Gong Y, Shaw KM, et al. PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network. J Amer Heart Assoc. 2019;8(9):e011246.","journal-title":"J Amer Heart Assoc."},{"key":"7452_CR34","first-page":"100201","volume":"21","author":"CJ Alanaeme","year":"2022","unstructured":"Alanaeme CJ, Bittner V, Brown TM, et al. Estimated number and percentage of US adults with atherosclerotic cardiovascular disease recommended add-on lipid-lowering therapy by the 2018 AHA\/ACC multi-society cholesterol guideline. Amer Heart J Plus. 2022;21:100201.","journal-title":"Amer Heart J Plus."},{"issue":"4","key":"7452_CR35","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1093\/aje\/kwab299","volume":"191","author":"JW Sun","year":"2022","unstructured":"Sun JW, Wang R, Li D, Toh S. Use of Linked Databases for Improved Confounding Control: Considerations for Potential Selection Bias. Am J Epidemiol. 2022;191(4):711\u201323.","journal-title":"Am J Epidemiol"},{"issue":"27","key":"7452_CR36","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1093\/eurheartj\/ehx450","volume":"39","author":"BA Ference","year":"2017","unstructured":"Ference BA, Cannon CP, Landmesser U, et al. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration. Eur Heart J. 2017;39(27):2540\u20135.","journal-title":"Eur Heart J"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-023-07452-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-023-07452-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-023-07452-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T16:08:26Z","timestamp":1727539706000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-023-07452-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,13]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["7452"],"URL":"https:\/\/doi.org\/10.1007\/s10557-023-07452-1","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,13]]},"assertion":[{"value":"30 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Review Board at the University of Alabama at Birmingham approved the study and waived the requirement to obtain informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"VAB was a national coordinator for Astra Zeneca (Long-Term Outcomes Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia [STRENGTH] trial) and DalCor (Dalgene trial) and is a national coordinator for Esperion (The Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen [CLEAR] outcomes study), all contracted between University of Alabama at Birmingham (UAB) and the trial sponsors; is a Steering Committee member for the Odyssey Outcomes Trial through a contract between UAB and Sanofi \/ Regeneron; serves as the site principal investigator for a contract between UAB and Novartis (HPS-4 TIMI 65 ORION-4 trial); was a consultant for Pfizer (until 2021) and is a co-investigator on a contract between the UAB School of Public Health and Amgen. TMB receives research support from Amgen, Inc. and served as the local site investigator for STRENGTH (Astra Zeneca). MEF receives research support from Amgen, Inc., Novo Nordisk, and Novartis. EBL receives research support from Amgen, Inc. and consulting fees Novartis. MMS receives research support from Amgen, Inc. MW serves as a consultant for Amgen, Inc., Freeline and Kyowa Kirin. ND, JJ, BK and JE are employees of and have stock in Amgen, Inc. PM receives research support and consulting fees from Amgen, Inc. RSR receives research support from Amgen, Arrowhead, Lilly, Novartis and Regeneron; consulting fees from Amgen, Arrowhead, CRISPR Therapeutics, Precision Biosciences, Novartis, Regeneron, Ultragenyx; honoraria for non-promotional speaking from Amgen, Lilly and Regeneron, royalties from Wolters Kluwer (UpToDate) and has stock holdings in MediMergent, LLC. LDC receives research support from Amgen, Inc. No other disclosures were reported.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}